Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Severe Hemophilia A: later-stage trial registry
2 of 5 indexed Severe Hemophilia A trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Severe Hemophilia A: 5 US clinical trials tracked, 2 recruiting.
Severe Hemophilia A is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Octapharma, running 2 of these trials.
Enrollment posture brief
Registry condition severe-hemophilia-a
OPEN 2 | RECR 40% | LATE 4 | EARLY 1 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Severe Hemophilia A lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Severe Hemophilia A on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Severe Hemophilia A is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Severe Hemophilia A research.
Octapharma accounts for 2 of 5 trials (40%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Severe Hemophilia A trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Severe Hemophilia A research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Octapharma
NCT05935358
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Pfizer
NCT06703606
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
Hoffmann-La Roche
NCT05181618
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
Hoffmann-La Roche
NCT04431726
Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
Octapharma
NCT01992549
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 2 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Severe Hemophilia A records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Severe Hemophilia A trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Severe Hemophilia A page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Severe Hemophilia A trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Octapharma sponsors the most Severe Hemophilia A trials on record, review their full trial history before evaluating a specific study. See Octapharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Severe Hemophilia A condition card totals 5 registered trials; most-linked intervention Emicizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.